Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | MPL | P40238 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872369 | 0.85 | KMO (0.55) | MPLHDAC1HDAC8HDAC6KMO | |
| SCHEMBL5901399 | 0.81 | HDAC1 (0.51) | HDAC1HDAC8HDAC6SCN10APDE4B | |
| SCHEMBL16242198 | 0.80 | HDAC1 (0.50) | HDAC1HDAC8HDAC6SCN10APDE4B | |
| SCHEMBL2221957 | 0.79 | HDAC1 (0.67) | HDAC1HDAC8HDAC6SCN10APDE4B | |
| SCHEMBL27401748 | 0.78 | NOTUM (0.47) | NOTUMHDAC1HDAC8HDAC6SCN10A | |
| SCHEMBL12907117 | 0.77 | HDAC1 (0.45) | HDAC1HDAC8HDAC6SCN10APDE4B | |
| SCHEMBL12943243 | 0.77 | HDAC1 (0.45) | HDAC1HDAC8HDAC6SCN10A | |
| SCHEMBL12563521 | 0.77 | PDE2A (0.48) | MPLHDAC1HDAC8HDAC6SCN10A | |
| SCHEMBL17487352 | 0.76 | HDAC1 (0.67) | HDAC1HDAC8HDAC6SCN10APDE4B | |
| SCHEMBL31163941 | 0.76 | HDAC1 (0.48) | HDAC1HDAC8HDAC6SCN10APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | NOTUM 4802/4885MPL 1/4885HDAC1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.